News
FDA Grants Priority Review to Belzutifan as Pheo/Para Treatment
The U.S. Food and Drug Administration (FDA) has granted priority review to Merck’s application for WELIREG® (belzutifan) as a treatment for adult and pediatric patients
Advancing NET Treatment: A New Molecule for More Effective Targeted Alpha Therapy
In 2021, NETRF funded Paul Schaffer, PhD, of the University of British Columbia, for a pilot project entitled “Preclinical Toxicity and Therapy Study of 225Ac-crown-TATE.”
NETRF Awards Ten Groundbreaking Research Grants to Advance Neuroendocrine Cancer Treatment
The Neuroendocrine Tumor Research Foundation (NETRF) has announced our newest neuroendocrine cancer research grant recipients. The ten investigators receiving awards are studying the most promising
Research Reveals Potential Risks of Popular GLP-1 Medications for Some with Neuroendocrine Cancer
A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type
NETRF represented at NANETS 2024
NETRF was well-represented at NANETS 2024, the annual meeting of the North American Neuroendocrine Tumor Society held in November. Several hundred physicians, researchers, and patient
From Hope to Promise: NETRF Research Symposium Brings the World’s Premier Neuroendocrine Cancer Researchers to Boston to Collaborate, Share Discoveries
NETRF’s 2024 Margie & Robert E. Petersen Neuroendocrine Tumor Research Symposium was held October 28-30 at The Hotel Commonwealth in Boston, Massachusetts. Our Symposium brought
Dr. Ajay Sharma Receives 2024 ERF/NETRF Nuclear Medicine Research Grant
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) and NETRF are proud to announce that Dr. Ajay Kumar Sharma has been
NETRF-funded Research Highlights Risks in Radiopharmaceutical Therapy for NETs
A new study has revealed that certain bone marrow cells may absorb more radiation during radiopharmaceutical therapy (RPT) than previously believed. This finding could explain
Cabozantinib Extends Progression-Free Survival in Phase 3 Clinical Trial
The investigational drug cabozantinib (CABOMETYX®) has significantly improved outcomes for those living with advanced neuroendocrine tumors (NETs), according to the latest results from the Phase
Study Opens the Door to Targeted, Personalized Treatments for Lung NETs
A recent study has unveiled key molecular insights that could transform the treatment landscape for lung neuroendocrine tumors (NETs). The Neuroendocrine Tumor Research Foundation provided